ESMO 2022 Prostate Cancer - Results from #20

Viewing 21-37 of 37 articles

ESMO 2022: Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints: A Post Hoc Analysis of the VISION Trial

ESMO 2022: Treatment Patterns and Overall Survival (OS) in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) from 2010 to 2019

ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic Castration Resistant Prostate Cancer (mCRPC): Initial Results from SPLASH

ESMO 2022: Treatment Efficacy and Safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer

ESMO 2022: Real-World First-Line Treatment Patterns in Patients with High-Risk nmCRPC

ESMO 2022: Lutetium-177-PSMA Therapy in Patients with Prior Radium-223: Safety and Effectiveness Outcomes in the RALU Study

ESMO 2022: Alkaline Phosphatase Decline and Pain Response as Markers for OS in Patients with mCRPC Treated with Radium-223 in the REASSURE Study

ESMO 2022: Additional Insights from the STAMPEDE Trial Platform

ESMO 2022: Effect of Abiraterone-Prednisone in mCSPC with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial

ESMO 2022: Quality of Life Across Three Countries Using a Large-Scale, Fully Digital Survey of Patients With Prostate Cancer

ESMO 2022: CYCLONE 3: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC

ESMO 2022: Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + Abiraterone Acetate and Prednisolone for mHSPC Starting ADT: OS Results of 2 Randomized Phase III Trials from the STAMPEDE Protocol

ESMO 2022: Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC

ESMO 2022: Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abiraterone and Placebo as First-Line Therapy for Patients with mCRPC

ESMO 2022: A Phase 1b Study of a Single Priming Dose of 177Lu-PSMA-617 Coupled with Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

ESMO 2022: PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)

ESMO 2022: Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial

1
2